Chiral Indolo[3,2-f][3]benzazecine-Type Dopamine Receptor Antagonists: Synthesis and Activity of Racemic and Enantiopure Derivatives
- 29 September 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (20) , 7422-7426
Abstract
Racemic and enantiopure 8-substituted derivatives of the lead dopamine receptor antagonist LE 300 (1) were prepared, and their affinities for the dopamine receptors (D1–D5) were tested. The separate enantiomers showed significantly different affinities; the (8S)-methyl and (8R)-hyroxymethyl derivatives where the substituents point below the reference plane of the indolo[3,2-f][3]benzazecine scaffold were markedly more active than their enantiomeric counterparts. The racemic 8-carboxy derivative was shown to be selective for the D5-receptor, even against D1.Keywords
This publication has 13 references indexed in Scilit:
- Residues at the Indole‐NH of LE300 Modulate Affinities and Selectivities for Dopamine ReceptorsArchiv der Pharmazie, 2010
- Neurobiology of addictionBiochemical Pharmacology, 2008
- Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonistsBioorganic & Medicinal Chemistry Letters, 2007
- The Role of Dopamine in the Pathophysiology of DepressionArchives of General Psychiatry, 2007
- Dopamine/Serotonin Receptor Ligands. 13: Homologization of a Benzindoloazecine-Type Dopamine Receptor Antagonist Modulates the Affinities for Dopamine D1−D5 ReceptorsJournal of Medicinal Chemistry, 2006
- Dopamine/Serotonin Receptor Ligands. 10: SAR Studies on Azecine-type Dopamine Receptor Ligands by Functional Screening at Human Cloned D1, D2L, and D5 Receptors with a Microplate Reader Based Calcium Assay Lead to a Novel Potent D1/D5 Selective AntagonistJournal of Medicinal Chemistry, 2005
- Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience researchBehavioural Brain Research, 2002
- 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: A New Heterocyclic System and a New Lead Compound for Dopamine Receptor AntagonistsJournal of Medicinal Chemistry, 2000
- Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal systemParkinsonism & Related Disorders, 1998
- Antipsychotic drug doses and neuroleptic/dopamine receptorsNature, 1976